非酒精性脂肪肝的药物治疗进展.pdfVIP

3666 ()2015 10 9 20 Chin J Clinicians(Electronic Edition),October 15,2015,Vol.9,No.20 NAFLD NASHMS NAFLD IR2 T2DMNAFLD NAFLD NAFLD Progress in drug treatment of nonalcoholic fatty liver disease Xu Liang, Mi Yuqiang. Department of Combination of Chinese Traditional and Western Medicine, The Second People’s Hospital of Tianjin, Tianjin Medical Research Institute of Liver Disease, Tianjin 300192, China Corresponding author: Mi Yuqiang, Email: yuqiangmi68@163.com Abstract Nonalcoholic fatty liver disease (NAFLD) is becoming the largest liver disease in China, and it has attracted more and more attention by bringing about not only liver disease, such as NASH, cirrhosis, hepatic carcinoma, but also cardiovascular and cerebrovascular diseases. So the therapy should take into account consideration not only NAFLD, but also other components of MS such as obesity, hyperlipidaemia, insulin resistance (IR), type 2 diabetes (T2DM), and so on. The therapy should include two sides, non-drug treatment-lifestyle modification, and drug treatment, and the former is basic treatment. Current drugs for treating NAFLD mainly include euglycemic agent, antioxidant, microecologics, descendens blood fat drugs, protecting liver function drugs, and traditional Chinese medicine. Key words Fatty liver; Nonalcoholic; Drug; Progress [4] non-alcohol fatty liver diseaseNAFLD [5] metabolic syndromeMS NAFLD NAFLD [1] insulin nonalcoholic simple fatty liverNAFL resistanceIR2 type 2 diabetesT2